Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab — Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Aniela Montserrat Silva Nolasco | Pharmaceutical Chemistry | Excellence in Research Award

Published on by Top Pharmaceutical

Excellence in Research Award


Aniela Montserrat Silva Nolasco

Universidad de Castilla-La Mancha, Spain


Aniela Montserrat Silva Nolasco
Affiliation Universidad de Castilla-La Mancha
Country Spain
Scopus ID
57221107566
Documents 21
Citations 23
h-index 2
Subject Area Pharmaceutical Chemistry
Event International Top Pharmaceutical Awards

Aniela Montserrat Silva Nolasco is a pharmaceutical science researcher associated with Universidad de Castilla-La Mancha, Spain. Her academic profile demonstrates research engagement in molecular pharmacology, pharmaceutical chemistry, cancer biology, and bioactive therapeutic compounds. Published studies associated with her scholarly work examine anticancer properties of argentatins, immunomodulatory activity, and translational therapeutic applications in oncology-related biomedical sciences.[1] Her research contributions are indexed through recognized academic databases including Scopus and ORCID, supporting international visibility and scientific dissemination within pharmaceutical and biomedical research communities.[2]

Abstract

This article summarizes the academic contributions and pharmaceutical research activities of Aniela Montserrat Silva Nolasco. The profile reflects scholarly involvement in cancer biology, molecular pharmacology, pharmaceutical chemistry, and translational therapeutic research involving argentatin compounds and related bioactive agents.[3] Indexed publications, DOI-linked research outputs, and collaborative scientific studies contribute to the researcher’s academic visibility within pharmaceutical and biomedical sciences.[4]

Keywords

Pharmaceutical Chemistry, Molecular Pharmacology, Anticancer Research, Argentatins, Cancer Biology, Translational Medicine, Immunomodulation, Biomedical Sciences, Oncology Research, Therapeutic Compounds.

Introduction

Pharmaceutical research associated with molecular therapeutics and cancer-related biomedical investigations continues to contribute substantially to contemporary translational medicine. Current scientific developments increasingly emphasize naturally derived compounds with potential therapeutic applications against tumor progression and immune dysregulation.[5] Research contributions associated with Aniela Montserrat Silva Nolasco demonstrate participation in this evolving pharmaceutical research landscape through investigations involving argentatins and cellular pharmacological mechanisms.[6]

Research Profile

The academic profile of Aniela Montserrat Silva Nolasco includes affiliations with Universidad de Castilla-La Mancha and previous research and educational activities associated with pharmaceutical and molecular sciences. Her scholarly background includes pharmaceutical biology, cellular pharmacology, and laboratory-based biomedical investigations relevant to therapeutic development and oncology-focused pharmaceutical sciences.[2]

The Scopus profile linked to the researcher identifies indexed publication activity, citation tracking, and collaborative research participation within pharmaceutical and biomedical disciplines. These indicators support measurable academic visibility and ongoing scholarly communication across internationally indexed scientific platforms.[1]

Research Contributions

Research contributions associated with Aniela Montserrat Silva Nolasco include investigations on argentatin compounds and their biological activity in cancer-related cellular environments. Published studies report antimigratory and antiangiogenic effects alongside analyses of long-term resistance induction associated with argentatin A and argentatin B.[3]

Additional scientific contributions address immunomodulatory activity isolated from guayule-derived compounds and synergistic therapeutic interactions involving 5-fluorouracil in colorectal cancer cell models. These studies contribute to broader translational pharmaceutical research exploring molecular therapeutic strategies in oncology-related biomedical sciences.[4]

Publications

The publication profile associated with Aniela Montserrat Silva Nolasco includes peer-reviewed research outputs indexed through recognized scientific databases. DOI-linked publications contribute to scholarly accessibility, research transparency, and international academic dissemination within pharmaceutical chemistry and molecular biomedical sciences.[3][4]

DOI-linked publications facilitate long-term accessibility and citation reliability within digital academic infrastructures. The use of persistent identifiers further supports research transparency, discoverability, and scholarly preservation across multidisciplinary scientific environments.[3]

Research Impact

Research impact is commonly evaluated using publication visibility, citation performance, indexed dissemination, and scholarly engagement across scientific communities. The researcher’s profile demonstrates documented participation in peer-reviewed pharmaceutical and biomedical research activities through Scopus-indexed publications and DOI-associated scholarly outputs.[1]

The available citation indicators and publication metrics support measurable academic relevance within specialized pharmaceutical chemistry and translational biomedical research domains. Continued scientific dissemination and collaborative publication activity may further strengthen long-term academic visibility and research influence.[2]

Award Suitability

The research activities and scholarly outputs associated with Aniela Montserrat Silva Nolasco align with the objectives of the International Top Pharmaceutical Awards through contributions to pharmaceutical chemistry, cancer-related therapeutic investigations, and molecular biomedical sciences.[6] The profile reflects participation in interdisciplinary scientific studies relevant to pharmaceutical innovation and translational therapeutic development.[3]

Conclusion

Aniela Montserrat Silva Nolasco has contributed to pharmaceutical and biomedical research through studies involving anticancer compounds, immunomodulatory activity, and molecular therapeutic investigations. Her academic profile demonstrates scholarly engagement within pharmaceutical chemistry and translational medicine, supported by indexed publications, collaborative research contributions, and DOI-linked scientific dissemination.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Aniela Montserrat Silva Nolasco, Author ID 57221107566. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221107566
  2. ORCID. (2026). Aniela M. Silva-Nolasco ORCID profile, affiliations, and academic activities.https://orcid.org/0000-0002-2134-7551
  3. Silva-Nolasco, A. M., Galvez, B. G., de la Cruz-Morcillo, M. A., & Carmona, M. (2026). Differential anti-cancer effects of argentatin A and B: antimigratory, antiangiogenic, and long-term resistance induction. Industrial Crops and Products.https://doi.org/10.1016/j.indcrop.2026.123255
  4. Silva-Nolasco, A. M., Singh, N., de la Cruz-Morcillo, M. A., García-Martínez, M. M., Zalacain, A., Gálvez, B. G., & Carmona, M. (2024). Immunomodulatory activity of argentatins A and B isolated from guayule. PLOS ONE.https://doi.org/10.1371/journal.pone.0304713
  5. Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024). Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models. Journal of Cellular and Molecular Medicine.https://doi.org/10.1111/jcmm.70294

Naglaa Shehab| Drug Discovery and Development | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Dr. Naglaa Shehab| Drug Discovery and Development | Research Excellence Award

Professor | Dubai Medical University | United Arab Emirates 

Prof. Naglaa Gamil Shehab is a Professor of Pharmaceutical Sciences at Dubai Medical University, specializing in pharmacognosy, phytochemistry, medicinal plants, and complementary medicine. She holds advanced degrees in pharmacognosy with a strong foundation in phytochemical research and natural product analysis. Her academic career spans progressive roles from teaching and research to senior professorship and academic leadership, including key responsibilities in curriculum development and coordination of multidisciplinary pharmaceutical courses. Her research focuses on the pharmacognostical and phytochemical investigation of medicinal plants, contributing to the validation of natural therapies and alternative medicine through scientific methodologies. With a notable citation record, consistent publication output, and measurable scholarly impact, she has established herself as a recognized contributor to pharmaceutical sciences. She is actively engaged in academic service through editorial contributions, professional memberships, and mentorship of emerging researchers, reflecting sustained commitment to advancing research quality and innovation in pharmacognosy and related disciplines.

Citation Metrics (Google Scholar)

779
600
400
200
0

779

18

14

Citations

i10-index

h-index


Top 5 Featured Publications

 

Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Published on by Top Pharmaceutical

Dr. Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Texas Tech University Health Science Center | United States

Dr. Hareesh B. Nair, Ph.D., is a distinguished biochemist and translational scientist whose career spans academia, biotechnology innovation, and advanced research leadership. He completed his academic training in life sciences and biochemistry in India, followed by specialized research fellowships in oxidative lipidomics and hormonal carcinogenesis at leading U.S. institutions. These early experiences laid the foundation for his lifelong commitment to understanding disease mechanisms and developing targeted therapeutic solutions.Dr. Nair’s professional journey reflects a rare blend of deep scientific expertise and strategic research leadership. Over the course of his career, he has held progressive roles ranging from instructor and assistant professor to senior scientist, director, and senior director of translational research and external innovation. His contributions at the University of Texas Health Science Center at San Antonio and the Texas Biomedical Research Institute significantly advanced the fields of breast cancer biology, hormonal carcinogenesis, melanoma signaling pathways, endometriosis, uterine fibroids, and targeted drug delivery. His work also includes pioneering estrogen-dependent cancer research, mechanistic studies on aromatase pathways, development of innovative cancer detection strategies, and creation of non-human primate models for reproductive disorders.At Evestra, Inc., Dr. Nair led multidisciplinary teams driving the translational development of oncology and women’s health therapeutics. He spearheaded multiple preclinical programs, established strategic collaborations, guided biomarker discovery, contributed to regulatory submissions, and supported business development through scientific due diligence. His leadership also resulted in the advancement of first-in-class and best-in-class therapeutic candidates, expansion of oncology pipelines, and successful acquisition of non-dilutive federal funding. His contributions include numerous publications, patents, and project management of large-scale contraceptive development initiatives supported by major global health foundations.In his current academic role at Texas Tech University Health Sciences Center El Paso, Dr. Nair is establishing a cutting-edge research laboratory at the chemistry–biology interface. His group focuses on identifying novel drug targets, decoding disease mechanisms, and transforming molecular insights into preclinical therapeutic strategies for cancers and other complex diseases. He remains deeply engaged in collaborative clinical and translational research, particularly in gynecologic oncology, triple-negative breast cancer, ovarian cancer, and endometrial cancer. His expertise also extends to long-acting contraceptive technologies, anti-HIV formulations, and experimental therapeutics for endometriosis and uterine fibroids.Beyond research, Dr. Nair has served extensively as a scientific review officer, facilitating numerous peer-review panels for federal biomedical research programs. His work has been recognized through multiple competitive honors, travel awards, and scientific achievement distinctions. With a strong commitment to innovation, mentorship, and multidisciplinary collaboration, Dr. Hareesh B. Nair continues to shape the future of translational medicine through impactful research, strategic leadership, and unwavering dedication to improving patient health outcomes.

Profile: Orcid

Featured Publications

Aller, E. J., Nair, H. B., Vadlamudi, R. K., & Viswanadhapalli, S. (2025). Significance of midkine signaling in women’s cancers: novel biomarker and therapeutic target. International Journal of Molecular Sciences, 26(10), 4809.

Blankenship, L., Pratap, U. P., Yang, X., Liu, Z., Altwegg, K. A., Santhamma, B., … Lai, Z. (2022). Inhibition of LIFR blocks adiposity‑driven endometrioid endometrial cancer growth. Cancers, 14(21), 5400.

Nair, H. B., Ford, A., Dick, E. J., Jr., Hill, R. H., Jr., & VandeBerg, J. L. (2014). Modeling sunscreen‑mediated melanoma prevention in the laboratory opossum (Monodelphis domestica). Pigment Cell & Melanoma Research, 27(5), 822‑830.

Nickisch, K., Nair, H. B., Kesavaram, N., Das, B., Garfield, R., Shi, S. Q., … Edwards, D. P. (2013). Synthesis and antiprogestational properties of novel 17‑fluorinated steroids. Steroids, 78(9), 895‑902.

Bhaskaran, S., Dileep, K. V., Deepa, S. S., Sadasivan, C., Klausner, M., Krishnegowda, N. K., … Nair, H. B. (2013). Gossypin as a novel selective dual inhibitor of V‑RAF murine sarcoma viral oncogene homolog B1 and cyclin‑dependent kinase 4 for melanoma. Molecular Cancer Therapeutics, 12(4), 567‑576.

Budrys, N. M., Nair, H. B., Liu, Y. G., Kirma, N. B., Binkley, P. A., Kumar, S., … Tekmal, R. R. (2012). Increased expression of macrophage colony‑stimulating factor and its receptor in patients with endometriosis. Fertility and Sterility, 97(5), 1159‑1165.e1.

Vijay Kumar | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Vijay Kumar | Drug Discovery and Development | Editorial Board Member

Dr B R Ambedkar NIT Jalandhar, India

Assoc. Prof. Dr. Vijay Kumar is a distinguished researcher, academician, and innovator in the fields of artificial intelligence, machine learning, biomedical informatics, cybersecurity, image processing, and computational intelligence. Over the course of his career, he has established himself as a prolific contributor whose research bridges advanced computational theories with real-world applications, particularly in healthcare, pandemic intelligence, medical imaging, network security, and autonomous systems. His academic journey is defined by a commitment to solving high-impact global challenges through intelligent algorithms, deep learning frameworks, optimization strategies, and secure data-driven technologies.Dr. Vijay Kumar’s scholarly work reflects exceptional depth and diversity. He has authored impactful publications in leading journals such as IEEE Transactions on Vehicular Technology, IEEE Journal of Biomedical and Health Informatics, Vaccine, Artificial Intelligence Review, Archives of Computational Methods in Engineering, Multimedia Tools and Applications, Computers in Biology and Medicine, and Biomedical Signal Processing and Control. His research spans a broad spectrum—from deepfake detection, autonomous vehicle visibility enhancement, multi-objective optimization, and cybersecurity frameworks, to intelligent diagnostic models for COVID-19, breast cancer, cervical cancer, and other critical diseases. His studies on advanced metaheuristic algorithms, chaotic encryption systems, drug synergy prediction, air-quality forecasting, and big healthcare data security have contributed significantly to modern computational science. A visionary in interdisciplinary AI, Dr. Kumar has collaborated extensively with international researchers, producing high-impact work on deep neural networks, generative adversarial models, hybrid optimization techniques, multimodal medical imaging, and cloud-based encryption systems. His contributions to pandemic preparedness, especially ML-driven vaccine development roadmaps and intelligent screening systems, highlight his dedication to translating technology into meaningful societal outcomes.He is also recognized for designing innovative algorithms such as lightweight NIDS architectures, evolutionary visibility restoration models, customized dehazing networks, and novel feature-selection optimizers. His body of work has become a reference point for emerging scholars in computer science, health informatics, and computational engineering.Dr. Vijay Kumar continues to lead transformative research, mentor young scientists, and contribute to global scientific advancement through his extensive publication record, collaborative projects, and commitment to innovation. His enduring academic excellence and forward-looking approach place him among the most influential researchers driving the future of intelligent systems and healthcare-focused artificial intelligence.

Profile: Google Scholar

Featured Publications

Katoch, S., Chauhan, S. S., & Kumar, V. (2020). A Review on Genetic Algorithm: Past, Present, and Future. Multimedia Tools and Applications, 52, 5252.

Dhiman, G., & Kumar, V. (2019). Seagull optimization algorithm: Theory and its applications for large‑scale industrial engineering problems. Knowledge‑Based Systems, 165, 169‑196.

Dhiman, G., & Kumar, V. (2017). Spotted Hyena Optimizer: A Novel Bio‑inspired based Metaheuristic Technique for Engineering Applications. Advances in Engineering Software, 114, 48‑70.

Dhiman, G., & Kumar, V. (2018). Emperor Penguin Optimizer: A Bio‑inspired Algorithm for Engineering Problems. Knowledge‑Based Systems, 159, 20‑50.

Singh, D., Kumar, V., Vaishali, & Kaur, M. (2020). Classification of COVID‑19 patients from chest CT images using multi‑objective differential evolution–based convolutional neural networks. European Journal of Clinical Microbiology & Infectious Diseases, 39, 1379‑1389.

Jaiswal, A., Gianchandani, N., Singh, D., Kumar, V., & Kaur, M. (2020). Classification of the COVID‑19 infected patients using DenseNet201 based deep transfer learning. Journal of Biomolecular Structure and Dynamics, 73, 1‑?.

Dhiman, G., Garg, M., Nagar, A., Kumar, V., & Dehghani, M. (2020). A Novel Algorithm for Global Optimization: Rat Swarm Optimizer. Journal of Ambient Intelligence and Humanized Computing, 5, 12‑?.

Das, N. N., Kumar, N., Kaur, M., Kumar, V., & Singh, D. (2020). Automated deep transfer learning‑based approach for detection of COVID‑19 infection in chest X‑rays. IRBM, 4, 25‑?.

Kaur, M., & Kumar, V. (2020). A comprehensive review on image encryption techniques. Archives of Computational Methods in Engineering, 27(1), 390.

Faiza Abou El-Soud | Formulation Science | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Faiza Abou El-Soud | Formulation Science | Best Researcher Award

College of Nursing-Riyadh King Saud bin Abdulaziz University for Health Sciences | Saudi Arabia

Prof. Faiza Abou El-Soud is a distinguished scholar and nursing educator whose work focuses on advancing health outcomes, improving the quality of patient care, and enriching the academic development of nursing students. With extensive expertise in nursing education, geriatric care, and psychosocial health, Professor Abou El-Soud has built a research portfolio that bridges theoretical understanding with practical application in healthcare and nursing practice. Her scholarly contributions reflect a commitment to evidence-based nursing, patient-centered care, and the empowerment of healthcare professionals through research-driven insights.Among her notable works is Nursing Students’ Perceptions toward Success and Failure Factors and their Academic Performance: A Descriptive Correlational Study, published in SYLWAN, which explores the academic determinants influencing nursing students’ success, offering valuable perspectives for educators seeking to improve nursing education outcomes. Another significant contribution, Impact of Self-Efficacy Theory on Improving Adherence of Older Adults Patients with Glaucoma’s Medication, published in the Journal of Health, Medicine and Nursing, applies psychological theory to practical nursing interventions, highlighting how self-efficacy principles can enhance medication adherence among older adults suffering from glaucoma.Professor Abou El-Soud has also made important contributions to geriatric health and community nursing through her publication Quality of Life, Self-Rated Health and Social Support among Older Adult in the Saudi Community in The Malaysian Journal of Nursing, where she and her co-authors assess the complex interplay between social support, perceived health, and overall life satisfaction among elderly populations. In another influential study, The Relationship between Health-Related Quality of Life and Burden among Family Caregivers of Elderly Patients Undergoing Hemodialysis in Saudi Arabia, published in the International Journal of Nursing Research, she investigates the emotional and physical challenges faced by caregivers, offering actionable insights to enhance support systems and healthcare strategies.Her collaborative work Impact of the Intrinsic and Extrinsic Motivation Factors on the Turnover Intention among Academic Staff, published in the IOSR Journal of Nursing and Health Science, examines motivational dynamics in academic environments and their influence on faculty retention, thereby contributing to the sustainability and advancement of nursing education institutions.

Profile: Google Scholar

Featured Publications

Salama, R. A., & Abou El-Soud, F. A. (n.d.). Caregiver burden from caring for impaired elderly: A cross-sectional study in rural Lower Egypt. Italian Journal of Public Health, 9(4), 103.

AlAnnaz, W. A. A., Gouda, A. D. K., Abou El-Soud, F. A., & Alanazi, M. R. (n.d.). Obesity prevalence and its impact on maternal and neonatal outcomes among pregnant women: A retrospective cross-sectional study design. Nursing Reports, 14(2), 1236–1250.

Hussein, A. A., & El-Soud, F. A. A. (n.d.). Developing an educational intervention and a standardized clinical assessment tool to promote clinical instructors assessment skills. The Fifteenth National Conference Evidence Based Practice.

Shaqiqi, W., & Abou El-Soud, F. A. (n.d.). The mediating role of social support on the relationship between secondary traumatic stress and burnout of nurses caring for COVID-19 patients: A cross-sectional study. Applied Nursing Research, 79, 151844.

Abou El-Soud, F. A., Alhoraim, S. A., Alammar, B. A., & Alotaibi, R. S. (n.d.). Quality of life, self-rated health and social support among older adult in the Saudi community. The Malaysian Journal of Nursing, 11(3), 13–25.

Al-Shehhi, M. S. M., & El-Soud, F. A. A. (n.d.). Factors affecting quality of life in patients with end-stage renal disease on hemodialysis, Ras Al Khaimah – United Arab Emirates. Journal of Health, Medicine and Nursing, 220–238.

Abou-El-Soud, F. A., Mohamed, H. F., & Prince, J. (n.d.). The effectiveness of training workshop in changing the tutors’ knowledge and attitude towards the integration of problem-based learning into nursing curriculum. International Journal of Nursing, 5.

Basant Farag | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Basant Farag | Drug Discovery and Development | Best Researcher Award

Zagazig University Faculty of Science | Egypt

Dr. Basant Farag is a distinguished organic chemist and assistant lecturer at the Department of Chemistry, Faculty of Science, Zagazig University, Egypt, with extensive expertise in the synthesis, biological evaluation, and computational studies of heterocyclic compounds. She completed her Ph.D. in Organic Chemistry at Zagazig University, building on her M.Sc. and B.Sc. degrees in the same field, demonstrating a consistent commitment to advancing chemical sciences. Her academic career encompasses teaching, mentoring students, and conducting cutting-edge research while serving as a teaching assistant and assistant lecturer, preparing lectures, evaluating students, and engaging in independent research projects. Dr. Farag is also an accomplished international reviewer for numerous journals including Chemistry Select, Eurasian Journal of Chemistry, Journal of Molecular Structure, Bioorganic Chemistry, and International Journal of Biological Macromolecules, highlighting her broad expertise and recognition in the global scientific community.Her research portfolio includes pioneering studies in the design and synthesis of biologically active heterocyclic compounds, focusing on pharmacologically relevant molecules with anticancer, antimicrobial, and antitubercular properties. Her notable publications include Synthesis and Molecular Docking of Some Novel 3-Thiazolyl-Coumarins as Inhibitors of VEGFR-2 Kinase, Mechanochemical Synthesis and Molecular Docking Studies of New Azines Bearing Indole as Anticancer Agents, Green Synthesis and Molecular Docking Study of Some New Thiazoles Using Terephthalohydrazide Chitosan Hydrogel as Ecofriendly Biopolymeric Catalyst, Green Route Synthesis and Molecular Docking of Azines Using Cellulose Sulfuric Acid under Microwave Irradiation, Synthesis, Molecular Docking and Anticancer Activity of Some 5-Aryl-5,10-Dihydropyrido[2,3-d:6,5-d′]Dipyrimidine-2,4,6,8-Tetraone Derivatives and Pyrido[2,3-d], Synthesis, Molecular Docking Study, and Biological Evaluation of New Thiadiazole and Thiazole Derivatives Incorporating Isoindoline-1,3-Dione Moiety as Anticancer and Antimicrobial Agents, Green Biocatalyst for Ultrasound-Assisted Thiazole Derivatives: Synthesis, Antibacterial Evaluation, and Docking Analysis, Cyanauric Chloride as a Key Precursor and a Core Component for Three-Armed Triazolopyrimidines: Recent Finding About SARs and Docking Analyses, Chitosan–Sulfonic Acid-Catalyzed Green Synthesis of Naphthalene-Based Azines as Potential Anticancer Agents, Synthesis, Molecular Docking, In Silico Study, and Evaluation of Bis-Thiazole-Based Curcumin Derivatives as Potential Antimicrobial Agents, and Design and Synthesis of Novel Hybrids Incorporating Thiadiazole or Thiazole-Naphthalene: Anticancer Assessment and Molecular Docking Study.

Profile: Google Scholar

Featured Publications

Abolibda, T. Z., Fathalla, M., Farag, B., Zaki, M. E. A., & Gomha, S. M. (n.d.). Synthesis and molecular docking of some novel 3-thiazolyl-coumarins as inhibitors of VEGFR-2 kinase. Molecules.

Ibrahim, M. S., Farag, B., Al-Humaidi, J. Y., Zaki, M. E. A., Fathalla, M., & Gomha, S. M. (n.d.). Mechanochemical synthesis and molecular docking studies of new azines bearing indole as anticancer agents. Molecules.

Gomha, S. M., Riyadh, S. M., Alharbi, R. A. K., Zaki, M. E. A., Abolibda, T. Z., & Farag, B. (n.d.). Green route synthesis and molecular docking of azines using cellulose sulfuric acid under microwave irradiation. Crystals.

Al-Humaidi, J. Y., Gomha, S. M., El-Ghany, N. A. A., Farag, B., Zaki, M. E. A., et al. (n.d.). Green synthesis and molecular docking study of some new thiazoles using terephthalohydrazide chitosan hydrogel as ecofriendly biopolymeric catalyst. Catalysts.

Hussein, A. M., Gomha, S. M., El-Ghany, N. A. A., Zaki, M. E. A., Farag, B., et al. (n.d.). Green biocatalyst for ultrasound-assisted thiazole derivatives: Synthesis, antibacterial evaluation, and docking analysis. ACS Omega.

Mokbel, W. A., Hosny, M. A., Gomha, S. M., Zaki, M. E. A., Farag, B., El Farargy, A. F., et al. (n.d.). Synthesis, molecular docking study, and biological evaluation of new thiadiazole and thiazole derivatives incorporating isoindoline-1,3-dione moiety as anticancer and antimicrobial agents. Results in Chemistry.

E Marimuthu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. E. Marimuthu | Drug Discovery and Development | Best Researcher Award

Professor at Arunachal University of Studies | Ayya Nadar Janaki Ammal College | Madurai Kamaraj University | India

Dr. E. Marimuthu is a dedicated researcher and academician specializing in plant biotechnology, microbiology, and molecular biology. With over 15 years of experience in research and education, he has made significant contributions through patents, microbial sequencing, and ethnobotanical surveys. His work focuses on endangered species conservation, natural IAA production, and nanomedicine applications for cancer. Dr. Marimuthu currently serves as a Professor at Arunachal University of Studies. His multidisciplinary efforts bridge traditional knowledge with modern scientific innovations, making him a standout figure in applied life sciences and pharmaceutical biotechnology.

Publication Profile 

Scopus 

Education

Dr. Marimuthu earned his Ph.D. from Madurai Kamaraj University in 2017, focusing on the in vitro conservation of endangered tree species in the Southern Western Ghats . He completed his M.Phil. and M.Sc. from Ayya Nadar Janaki Ammal College, conducting ethnomedicinal surveys and plant growth hormone studies. His academic foundation began with a B.Sc. in Botany. Each academic milestone has been rooted in biodiversity conservation and plant-microbe interactions, establishing a strong base for his later patents and microbial gene discoveries .

Experience

Dr. Marimuthu has held various academic and research roles: Professor and Associate Professor at Arunachal University of Studies (2023–present), Assistant Professor at Sri Vidya Mandir and Vivekanandha Colleges, and Associate Scientist at Aakash Green Research Pvt. Ltd. Earlier, he served as a JRF at TBGRI, Kerala  and Technical Assistant at Kalasalingam University. His experience spans plant tissue culture, cell line work, and microbial molecular studies. With deep involvement in both lab and field research, he has nurtured innovations from concept to patent, while also mentoring students and contributing to curriculum development.

Awards 

Dr. E. Marimuthu is a prolific innovator with 8 Indian patents and 2 Canadian patents, showcasing breakthroughs in nanomedicine, cancer immunotherapy, and plant-based biotechnology . His bacterial gene sequences are submitted to NCBI, emphasizing novel microbial discoveries from unique ecological niches. Recognized nationally and internationally for his translational research, he has pioneered techniques that merge traditional plant knowledge with high-end scientific platforms. Though specific named awards are not listed, his patent record and academic promotions signify a distinguished and respected trajectory in bioscience innovation and interdisciplinary research.

Research Focus 

Dr. Marimuthu’s research emphasizes plant tissue culture, natural growth hormone production, ethnomedicinal conservation, and nanotechnology-enhanced drug delivery . He explores molecular markers for documenting genetic diversity and has successfully isolated bacterial strains producing Indole-3-acetic acid (IAA) to promote plant growth . He integrates ethnobotanical knowledge with biotechnological advancements to develop eco-friendly, scalable solutions for agriculture and medicine. His cutting-edge work in cancer-targeting mesenchymal stem cell therapy, as well as nano-immunotherapy, reflects a visionary outlook on the future of personalized medicine and sustainable pharmacology.

Publication Top Notes

Title: Chemical profiling and in silico molecular docking studies of phytochemicals from Hydnocarpus macrocarpa Warb: A GC–MS, FTIR, and physico-chemical analysis
Journal: Journal of Molecular Structure
Year: 2025

Conclusion

Dr. E. Marimuthu is an outstanding candidate for the Best Researcher Award, showcasing a rare combination of field knowledge, lab precision, patent-oriented innovation, and a commitment to both fundamental and applied science. His work contributes significantly to biotechnology, pharmacology, environmental microbiology, and regenerative agriculture.

Khaydar Yunusov | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Khaydar Yunusov | Drug Discovery and Development | Best Researcher Award

Prof. Khaydar Yunusov at Institute of Polymer Chemistry and Physics Uzbekistan Academy of Sciences, Uzbekistan.

Prof. Khaydar Yunusov is a distinguished polymer chemist from Uzbekistan with extensive expertise in nanotechnology, cellulose chemistry, and biomaterials. Since 2007, he has held key research and leadership roles at the Institute of Polymer Chemistry and Physics, contributing significantly to polymer-based biomedical innovations. 💊 He holds a Doctor of Science and leads groundbreaking projects on nanostructured antibacterial films, antiviral eye medications, and burn treatments. 📘 With several patents, international collaborations 🌍, and editorial roles in leading journals, Prof. Yunusov is a pioneering force in sustainable polymer research and nanomedical applications.

Publication Profile 

Orcid

Education

Prof. Khaydar Yunusov began his academic journey at the Tashkent Chemical Technological Institute, earning a Bachelor’s degree in Chemistry (2006) and a Master’s in Cellulose, Paper Chemistry, and Technology (2008). 📘 Driven by scientific excellence, he pursued a Doctor of Science in Technical Sciences (2009–2016), focusing on advanced polymer research. Since 2018, he has served as a Senior Scientific Researcher in Nanochemistry, Nanophysics, and Nanotechnology. 🧪 His research delves into nanostructured bactericidal preparations based on cellulose and its derivatives, emphasizing synthesis, properties, and production technologies. 🧬 His academic background provides a solid foundation for pioneering innovations in polymer science.

Experience

Prof. Khaydar Yunusov has cultivated a rich professional career in polymer science, beginning in 2007 as a researcher at the Institute of Polymer Chemistry and Physics, Uzbek Academy of Sciences, Tashkent. 📍 Over the years, he advanced through roles including junior researcher, senior researcher, and project manager, earning his Doctor of Science along the way. 🔬 His expertise spans polymer and cellulose chemistry, nanotechnology, and biomaterials. From 2019 to 2023, he served as a lab and project manager, driving innovation in nanostructured materials. 💼 Prof. Yunusov’s professional path reflects unwavering dedication to scientific discovery and technological advancement.

Research Focus 

Prof. Khaydar Yunusov is a pioneering scientist whose research spans polymer chemistry, cellulose technology, and nanochemistry. His core focus lies in designing biocompatible nanomaterials 🧫 such as nanostructured drug delivery systems, microneedles, hydrogels, and functional films for medical applications 🎯. He actively explores biodegradable polymers, nanoparticle synthesis (silver, selenium, zinc oxide), and antimicrobial and anticancer therapies 💊. His work intersects biotechnology, materials science, and pharmaceutical engineering, advancing targeted treatments and regenerative medicine 🧠🦠. With numerous high-impact publications, Prof. Yunusov is shaping the future of smart biomaterials and sustainable polymeric solutions.

Publication Top Notes

  • A red cell membrane-camouflaged nanoreactor for enhanced starvation/chemodynamic/ion interference therapy for breast cancer
  • A three-dimensional printable conductive composite dressing for accelerating wound healing under electrical stimulation
  • Core-shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management ( vol 12, pg 1064, 2024)
  • Fabrication of hollow microneedles with double-layer shell structure for rapid and prolonged local anesthesia
  • Homemade isothermal amplification-initiated Cas14a assay for rapid quantitative detection of aquatic RNA virus gene with no PAM
  • Iontophoresis-driven transdermal drug delivery system based on porous microneedles for hyperuricemia treatment
  • Real-time microbial growth curve (RMGC) system: an improved microplate reader with a graphical interface for automatic and high-throughput monitoring of microbial growth curves
  • Two-directions mechanical strength and high-barrier mechanisms of cellulose nanocrystal- based hybrids reinforced packaging with nacre-mimetic structure
  • Physico-chemical characteristics of dialdehyde carboxymethylcellulose/sericin graft copolymer
  • Synthesis, Characterization, and Cytotoxic Activity of Stable Selenium Nanoparticles‐Incorporated Carboxymethylcellulose Solution
  • Impact of cellulose supramolecular structure on its carboxymethylation reaction activity
  • Advances in the formation and properties of nanofiber biomaterials from polyvinyl alcohol/carboxymethylcellulose/nanosilver systems for medical applications
  • Obtaining Dialdehyde Carboxymethylcellulose Through Microwave Treatment
  • Core-shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management

Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile 

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

  • Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer
  • Design and progress of drug-loading polymeric bead for tumor embolization
  • Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?
  • Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells
  • Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma